BRIEF-Biomarin- gets European orphan drug designation for Gene Therapy drug for Hemophilia A

* Receives European orphan drug designation for bmn 270,

first investigational aav-factor viii gene therapy for patients

with hemophilia a

Source text for Eikon:

Further company coverage:

Read more